AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00937170 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zimmer High Flex LPS Implant (Total knee replacement)
Description: Outcomes comparison between a gender specific total knee implant, a standard total knee implant by the same company, and a standard total knee implant from another company
Study NCT00937170 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stryker Triathlon Implant (Total knee replacement)
Description: Outcomes comparison between a gender specific total knee implant, a standard total knee implant by the same company, and a standard total knee implant from another company
Study NCT04373915 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Bedside Rounding
Description: Parents of infants on the medical team utilizing remote rounding will have the opportunity to participate in rounds by video conferencing at the infant's bedside. Participation will be tracked and surveys regarding stress, satisfaction, and attachment will be completed by parents in both groups.
Study NCT02127320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg
Study NCT02127320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10mg
Study NCT02127320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg + Ezetimibe 10mg
Study NCT03508999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole gel
Description: The application of metronidazole gel is effective in the management of gingivitis in patients undergoing orthodontic therapy. Additionally, the constant reminder therapy at weekly interval would also lead to improvement in the oral hygiene.16 According to pertinent literature survey, none of the study has been conducted to compare the effectiveness of SMS reminders and use of anaerobic gel to reduce gingival inflammation.
Study NCT03481374 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: autonomic function testing
Description: autonomic function testing, ergospirometry, three questionnaires~Other Names:~* The autonomic function tests consist of five tests:~  * The Valsalva maneuver~ * The isometric handgrip test~ * The deep breathing test~ * The cold pressor test~ * A short head-up tilt test~* A maximal ergospirometry~* Three questionnaires:~  * EQ-5D-3L: quality of life~ * IPAQ: capacity to do physical activities
Study NCT03481374 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: autonomic function testing
Description: autonomic function testing, ergospirometry, three questionnaires~Other Names:~* The autonomic function tests consist of five tests:~  * The Valsalva maneuver~ * The isometric handgrip test~ * The deep breathing test~ * The cold pressor test~ * A short head-up tilt test~* A maximal ergospirometry~* Three questionnaires:~  * EQ-5D-3L: quality of life~ * IPAQ: capacity to do physical activities
Study NCT02486640 — intervention group
Intervention type: DRUG
Intervention: Interferon beta-1b (Betaferon, BAY86-5046)
Description: Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect autoinjector.
Study NCT02486640 — intervention group
Intervention type: DEVICE
Intervention: Betaconnect Autoinjector
Description: Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect autoinjector.
Study NCT00669643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PB 6 doses - Rifampicin and Dapsone
Description: Adult: 6 doses;~1 monthly supervised dose: 600 mg Rifampicin + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone;~Children: 6 doses;~1 monthly supervised dose: 450 mg Rifampicin + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone
Study NCT00669643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB 6 doses - Rifampicin, Clofazimine and Dapsone
Description: Adult: 6 doses;~1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine;~Children: 6 doses;~1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine
Study NCT00669643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB 12 doses - Rifampicin, Clofazimine and Dapsone
Description: Adult: 12 doses;~1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine;~Children: 12 doses;~1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine
Study NCT00669643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB 6 doses - Rifampicin, Clofazimine and Dapsone
Description: Adult: 6 doses~1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine~Children: 6 doses~1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine
Study NCT03577977 — intervention group
Intervention type: DRUG
Intervention: Interferon beta-1b (Betaseron, Betaferon, BAY86-5046)
Description: Betaferon was injected subcutaneously as prescribed by the treating physician.
Study NCT00065637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Synthetic human parathyroid hormone
Study NCT00065637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo teriparatide
Description: Placebo injections
Study NCT03590535 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 4th Gen cTnT
Description: Current Fourth Generation Cardiac Troponin T Enzyme Assay
Study NCT03590535 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 5th Gen cTnT
Description: New Fifth Generation (High-sensitivity) Troponin T Enzyme Assay
Study NCT03508999 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: SMS text reminder
Description: Subjects will be provided biweekly reminder via 'SMS text reminder' in the form of text message reinforcing oral hygiene. Additionally, patients will be given standard oral hygiene instructions on the visit with a placebo gel topically instructed to apply on the marginal gingiva for the next 4 weeks, twice a day for 30 minutes, after morning and evening tooth brushing.
Study NCT03508999 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Group C will be subjects will be given standard oral hygiene instructions on the visit with a placebo gel topically instructed to apply on the marginal gingiva for the next 4 weeks, twice a day for 30 minutes, after morning and evening tooth brushing.
Study NCT01183702 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LASIK surgery
Description: Participants have received LASIK surgery and their eyes are healthy.
Study NCT01183702 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Intervention
Description: Participant has healthy eyes not altered by LASIK surgery.
Study NCT01188876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given intravenously on Day 1 of each 28-day cycle
Study NCT01188876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pralatrexate
Description: Given intravenously on Day 1 and Day 15 of each 28-day cycle.
Study NCT01188876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Given orally on a daily basis starting 7 days before the first dose of pralatrexate and continuing until 30 days after the last dose of pralatrexate.
Study NCT01188876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B12 Injection
Description: Given vitamin B12 injection no more than 10 weeks prior to the first dose of pralatrexate and every 8-10 weeks after the first dose of pralatrexate.
Study NCT01113645 — intervention group
Intervention type: PROCEDURE
Intervention: Cerebral perfusion evaluation
Description: The patient who received a craniectomy is included in the study and an information notice given to him. All patients are evaluated by GOS (Glasgow Outcome Score) and neurocognitive tests by FAB (frontal assessment battery) and MMSE (mini mental state examination) scores 1 week prior and 6 and 24 weeks post cranioplasty. Furthermore, hemodynamic monitoring is performed by CT perfusion scan (with quantitative assessment of global and local cerebral flow) 1 week prior and 6 weeks post cranioplasty, as well as by trans-cranial Doppler 1 week prior and 6 and 24 weeks post cranioplasty.
Study NCT01490606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: knee OA project
Description: physical therapy in OA Knee project, total of 12 sessions, 6 group therapies amd 6 one on one therapy.
Study NCT01490606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional PT
Description: 12 SESSIONS OF CONVENTIONAL PHYSICAL THERAPY
Study NCT00614120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 0.6 mg/day, s.c. (under the skin) injection
Study NCT00614120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Glimepiride placebo, capsules
Study NCT00614120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 1.2 mg/day, s.c. (under the skin) injection
Study NCT00614120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 1.8 mg/day, s.c. (under the skin) injection
Study NCT00614120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glimepiride
Description: Capsules, 4.0 mg/day
Study NCT00614120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Tablets, 1.5-2.0 g/day
Study NCT00614120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Liraglutide placebo, s.c. (under the skin) injection
Study NCT00923182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Study NCT03722745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TARGET
Description: TARGET is manualized cognitive-behavioral treatment designed to help adolescents and adults with symptoms of posttraumatic stress
Study NCT03722745 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: It involves referral to an offsite community mental health provider with no attempt to control the treatment modality-type-quality (i.e., evidence-based-treatment or not).
Study NCT00746824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TM30339 and/or placebo
Description: The drug and/or placebo will be injected in the abdominal area (site to vary for each injection). Injections will be administered twice daily for 28 days.
Study NCT00721344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere Inhalation Powder (FDKP)
Description: Technosphere® Inhalation Powder 20mg
Study NCT00721344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Tablets 400mg
Study NCT00721344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere Inhalation Powder (FDKP)
Description: Technosphere® Inhalation Powder 40mg
Study NCT00721344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo cartridges
Study NCT03439540 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plantago major
Description: Individuals receive Plantago major daily, for 12 weeks
Study NCT03439540 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Individuals receive placebo daily, for 12 weeks
Study NCT04487483 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep App
Description: A sleep app offering 6 evidence based techniques to improve sleep (such as Cognitive Behavioural Therapy for Insomnia, Progressive Muscle Relaxation and Mindfulness Meditation), allowing for a personally tailored journey of sleep aids within the app.
Study NCT02083055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: controlled hypotensive anesthesia with dexmedetomidine compare with nitroglycerin on anesthetic outcome such as analgesic use, time to eye opening, follow verbal command, extubation and early postoperative pain
Study NCT02083055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin
Description: controlled hypotensive anesthesia with nitroglycerin compared with dexmedetomidine on anesthetic outcomes such as analgesic use, time to eye opening, follow verbal command, extubation, and early postoperative pain.
Study NCT01594892 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiosurgery
Description: Fractionated radiosurgery using intensity-modulated treatment planning and volumetric image-guided treatment delivery
Study NCT04097795 — intervention group
Intervention type: OTHER
Intervention: Prehabilitation
Description: According to our definition, prehabilitation consists of exercise therapy during at least 2 weeks. This is combined with optimalisation of the patients' nutritional status at least 2 weeks before surgery.
Study NCT00725608 — intervention group
Intervention type: DRUG
Intervention: buprenorphine/naloxone
Description: 2/0.5 mg buprenorphine/naloxone and 8/2 mg buprenorphine/naloxone sublingual tablets; dosage and frequency are subject specific; subjects will receive treatment for up to 12 months
Study NCT02048917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Intensity Counseling + Long Acting NRT + PRN NRT
Description: High Intensity Counseling + Long Acting NRT + PRN NRT
Study NCT02048917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Intensity Counseling + bupropion + PRN NRT
Description: High Intensity Counseling + bupropion + PRN NRT
Study NCT02048917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Intensity Counseling + varenicline + PRN NRT
Description: High Intensity Counseling + varenicline + PRN NRT
Study NCT02048917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Intensity Counseling + Long Acting NRT
Description: High Intensity Counseling + Long Acting NRT
Study NCT02048917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Intensity Counseling + bupropion
Description: High Intensity Counseling + bupropion
Study NCT02048917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Intensity Counseling + varenicline
Description: High Intensity Counseling + varenicline
Study NCT02048917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Intensity Counseling + Long Acting NRT + PRN NRT
Description: Low Intensity Counseling + Long Acting NRT + PRN NRT
Study NCT02048917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Intensity Counseling + bupropion + PRN NRT
Description: Low Intensity Counseling + bupropion + PRN NRT
Study NCT02048917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Intensity Counseling + varenicline + PRN NRT
Description: Low Intensity Counseling + varenicline + PRN NRT
Study NCT02048917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Intensity Counseling + Long Acting NRT
Description: Low Intensity Counseling + Long Acting NRT
Study NCT02048917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Intensity Counseling + bupropion
Description: Low Intensity Counseling + bupropion
Study NCT02048917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Intensity Counseling + varenicline
Description: Low Intensity Counseling + varenicline
Study NCT03676114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: 0.5mg/kg intravenous ketamine injection before incision followed by 0.25mg/kg/hr intravenous ketamine infusion during the operation
Study NCT03676114 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Same volume of normal saline will be administrated
Study NCT02648477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Given PO
Study NCT02648477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT02648477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Given PO
Study NCT02648477 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02648477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO
Study NCT02648477 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT02215863 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluad and Prevenar13
Study NCT02215863 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluad
Study NCT02215863 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar13
Study NCT03249597 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test: Glukos, SuPAR, Laktat and HBP
Description: Four blood tests described in the section Biospecimen Description are analyzed within the main study; Glukos, SuPAR, Laktat and HBP.
Study NCT00108485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended release niacin
Description: Extended release niacin 1500-2000mg once daily
Study NCT00108485 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study NCT03358771 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: COPD discharge care bundle
Description: As a part of RHSCN quality improvement initiative, the elements of the COPD discharge bundle were integrated into a standardized COPD admission order set and are being implemented province-wide. The discharging physician/team will complete the COPD bundle (with reminders facilitated by clinical decision support tools) prior to patient discharge. A copy of the bundle is retained in the patient's medical record, and another copy is sent to the patient's primary care provider detailing the components of the bundle that were completed prior to discharge, and those still needing to be addressed. The patient will also receive a patient-focused discharge checklist detailing discharge bundle items
Study NCT03358771 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COPD discharge care bundle & coordinator
Description: The coordinator will be health professional associated with a Primary Care Network, ED or AHS with access to patient information. Patients will be informed that care coordinator may contact them for follow up after discharge. At 48-72 hours after hospital/ED discharge and then at intervals to be determined, the care coordinator will contact the patient by phone. The care coordinator will identify specific needs or problems that patient may have encountered after discharge, which could potentially affect the successful transition from acute to community care setting. Specifically, the care coordinator will seek information on any follow up with family doctor visit, pulmonary rehabilitation and smoking cessation referrals
Study NCT02545361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAHR-102
Description: KAHR-102 is a dual signaling protein (DSP).KAHR-102 will be administrated subcutaneously. In Stage 1A, 3 KAHR-102 SC injections will continue to be given every 14 days with an interval of 28 days after 1st cycle and 14 days after 2nd cycle and following cycles.~In Stage 1B and Stage 2, subjects will be administered 3 KAHR-102 SC injections given every 7 days with an interval of 28 days after 1st cycle and 14 days after 2nd cycle and following cycles.~Planned doses for stage 1:~Cohort A: 2µg/kg Cohort B: 4 µg/kg Cohort C: 8 µg/kg Cohort D: 12 µg/kg Each cohort will only begin its first administration of KAHR-102 SC injection when the cohort preceding it will not meet criteria for a DLT (at least 7 days).
Study NCT04521621 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gebasaxturev
Description: Participants receive gebasaxturev intratumorally for 1 28-day cycle followed by 7 21-day cycles.
Study NCT04521621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants receive pembrolizumab intravenously for 1 28-day cycle followed by 34 21-day cycles.
Study NCT03369067 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tandem t:slim X2 with Control-IQ Technology + Dexcom G6
Description: Subjects will use the Tandem t:slim X2 with Control-IQ Technology and Dexcom G6 CGM to control their glycemia. The Tandem t:slim X2 with Control-IQ device is an automated insulin delivery pump that automatically adjusts insulin delivery to predicted and prevailing glucose levels, as measured by a Dexcom G6 continuous glucose monitor \[CGM\].
Study NCT03369067 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom CGM G5
Description: The Dexcom G5 CGM is a subcutaneous glucose sensor that provides an estimate of the prevailing blood glucose concentration approximately every 5 minutes.The Dexcom G5 sensor alerts the user if the prevailing glucose concentration is higher or lower than predetermined thresholds, or if it is changing too fast. In addition, the Share/Follow functionality of the Dexcom G5 allows up to 5 people (followers) to receive in real-time information about the current blood glucose concentration and rate of change.~The Dexcom G5 system will be used by participants and clinical study staff to monitor glucose levels 24h/day during the camp, ensure participants safety, and compute glycemic control outcomes